Article
Oncology
R. Kanesvaran, E. Castro, A. Wong, K. Fizazi, M. L. K. Chua, Y. Zhu, H. Malhotra, Y. Miura, J. L. Lee, F. L. T. Chong, Y-S Pu, C-C Yen, M. Saad, H. J. Lee, H. Kitamura, K. Prabhash, Q. Zou, G. Curigliano, E. Poon, S. P. Choo, S. Peters, E. Lim, T. Yoshino, G. Pentheroudakis
Summary: To accommodate the specific requirements of prostate cancer treatment in Asia, a special meeting was convened by ESMO and SSO to revise the guidelines published in 2020. These guidelines represent the consensus opinions of prostate cancer treatment experts from Asian countries and aim to provide optimization and harmonization recommendations for the management of prostate cancer patients across different regions in Asia.
Article
Oncology
T. Yoshino, G. Argiles, E. Oki, E. Martinelli, H. Taniguchi, D. Arnold, Mishima, Y. Li, B. K. Smruti, J. B. Ahn, I. Faud, C. E. Chee, K. -h. Yeh, P. -c. Lin, C. Chua, H. H. Hasbullah, M. A. Lee, A. Sharma, Y. Sun, G. Curigliano, H. Bando, F. Lordick, T. Yamanaka, J. Tabernero, E. Baba, A. Cervantes, A. Ohtsu, S. Peters, C. Ishioka, G. Pentheroudakis
Summary: The ESMO 2020 guidelines for localised colon cancer were adapted to account for ethnic differences in Asian patients during a special virtual meeting convened by ESMO and JSMO in March 2021. These guidelines represent the consensus opinions of experts from various oncological societies in Asia, and the voting was based on scientific evidence.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
T. Yoshino, A. Cervantes, H. Bando, E. Martinelli, E. Oki, R. -H. Xu, N. A. Mulansari, K. Govind Babu, M. A. Lee, C. K. Tan, G. Cornelio, D. Q. Chong, L. -T. Chen, S. Tanasanvimon, N. Prasongsook, K. -H. Yeh, C. Chua, M. D. Sacdalan, W. J. Sow (Jenson), S. T. Kim, R. T. Chacko, R. A. Syaiful, S. Z. Zhang, G. Curigliano, S. Mishima, Y. Nakamura, H. Ebi, Y. Sunakawa, M. Takahashi, E. Baba, S. Peters, C. Ishioka, G. Pentheroudakis
Summary: The ESMO Guidelines for metastatic colorectal cancer (mCRC) were adapted to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for Asian patients. The guidelines were developed by a panel of experts from Asian oncological societies, based on scientific evidence and independent of treatment practices and reimbursement decisions. The aim is to optimize and harmonize the management of mCRC across Asia, considering the differences in screening practices, molecular profiling, and drug approvals and reimbursement strategies.
Article
Oncology
R. Kanesvaran, C. Porta, A. Wong, T. Powles, Q. S. Ng, M. Schmidinger, D. Ye, H. Malhotra, Y. Miura, J. L. Lee, F. L. T. Chong, Y-S Pu, C-C Yen, M. Saad, H. J. Lee, H. Kitamura, G. S. Bhattacharyya, G. Curigliano, E. Poon, S. P. Choo, S. Peters, E. Lim, T. Yoshino, G. Pentheroudakis
Summary: The ESMO and SSO held a special virtual guidelines meeting in May 2021 to adapt the 2019 guidelines for renal cell carcinoma treatment to account for ethnic differences in Asian patients. Expert opinions from oncological societies in China, India, Japan, Korea, Malaysia, Singapore, and Taiwan were considered based on scientific evidence independent of current treatment practices and drug access restrictions in Asian countries.
Article
Oncology
S. J. Strauss, A. M. Frezza, N. Abecassis, J. Bajpai, S. Bauer, R. Biagini, S. Bielack, J. Y. Blay, S. Bolle, S. Bonvalot, I Boukovinas, J. V. M. G. Bovee, K. Boye, B. Brennan, T. Brodowicz, A. Buonadonna, E. de Alava, A. P. Dei Tos, X. Garcia Del Muro, A. Dufresne, M. Eriksson, F. Fagioli, A. Fedenko, V Ferraresi, A. Ferrari, N. Gaspar, S. Gasperoni, H. Gelderblom, F. Gouin, G. Grignani, A. Gronchi, R. Haas, A. B. Hassan, S. Hecker-Nolting, N. Hindi, P. Hohenberger, H. Joensuu, R. L. Jones, C. Jungels, P. Jutte, L. Kager, B. Kasper, A. Kawai, K. Kopeckova, D. A. Krakorova, A. Le Cesne, F. Le Grange, E. Legius, A. Leithner, A. Lopez Pousa, J. Martin-Broto, O. Merimsky, C. Messiou, A. B. Miah, O. Mir, M. Montemurro, B. Morland, C. Morosi, E. Palmerini, M. A. Pantaleo, R. Piana, S. Piperno-Neumann, P. Reichardt, P. Rutkowski, A. A. Safwat, C. Sangalli, M. Sbaraglia, S. Scheipl, P. Schoffski, S. Sleijfer, D. Strauss, K. Sundby Hall, A. Trama, M. Unk, M. A. J. van de Sande, W. T. A. van der Graaf, W. J. van Houdt, T. Frebourg, R. Ladenstein, P. G. Casali, S. Stacchiotti
Summary: The paragraph lists the names of various researchers, possibly in the author list of a research paper.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
S. Koppikar, A. Oaknin, K. Govind Babu, D. Lorusso, S. Gupta, L. -Y. Wu, W. Rajabto, K. Harano, S. -h. Hong, R. A. Malik, H. Strebel, I. M. Aggarwal, C. -H. Lai, T. Dejthevaporn, S. Tangjitgamol, W. F. Cheng, W. Y. Chay, D. Benavides, N. M. Hashim, Y. W. Moon, M. Yunokawa, T. D. Anggraeni, W. Wei, G. Curigliano, A. Maheshwari, U. Mahantshetty, S. Sheshadri, S. Peters, T. Yoshino, G. Pentheroudakis
Summary: The European Society for Medical Oncology (ESMO) published the most recent version of their guidelines for endometrial cancer in 2022. In order to account for variations in endometrial cancer management in Asia, a virtual meeting was held in July 2022 to adapt the ESMO guidelines. The guidelines represent the consensus opinion of Asian experts from various oncological societies. The aim is to provide guidance for the management of endometrial cancer in different regions of Asia, considering variations in clinical presentation, diagnostic practices, and access to treatment options.
Article
Oncology
S. -A. Im, A. Gennari, Y. H. Park, J. H. Kim, Z. -F. Jiang, S. Gupta, T. H. Fadjari, K. Tamura, M. Y. Mastura, M. L. T. Abesamis-Tiambeng, E. H. Lim, C. -H. Lin, A. Sookprasert, N. Parinyanitikul, L. -M. Tseng, S. -C. Lee, P. Caguioa, M. Singh, Y. Naito, R. A. Hukom, B. K. Smruti, S. -S. Wang, S. B. Kim, K. -H. Lee, H. K. Ahn, S. Peters, T. W. Kim, T. Yoshino, G. Pentheroudakis, G. Curigliano, N. Harbeck
Summary: The most recent version of the ESMO Clinical Practice Guidelines for metastatic breast cancer was published in 2021. In 2022, a special hybrid guidelines meeting was held to adapt these guidelines to the Asian context, with input from Asian oncology societies. The aim is to provide harmonized management of MBC patients across Asia.
Article
Oncology
B. Keam, J-P Machiels, H. R. Kim, L. Licitra, W. Golusinski, V Gregoire, Y. G. Lee, C. Belka, Y. Guo, S. J. Rajappa, M. Tahara, M. Azrif, M. K. Ang, M-H Yang, C-H Wang, Q. S. Ng, W. I. Wan Zamaniah, N. Kiyota, S. Babu, K. Yang, G. Curigliano, S. Peters, T. W. Kim, T. Yoshino, G. Pentheroudakis
Summary: ESMO and KSMO convened a special virtual guidelines meeting in July 2021 to adapt the ESMO 2020 guidelines to consider potential ethnic differences in Asian patients' treatment of SCCs of the head and neck. These guidelines represent consensus opinions from experts across Asia and provide expert recommendations for the diagnosis, treatment, and management of patients with SCC of the oral cavity, larynx, oropharynx, and hypopharynx.
Article
Medicine, General & Internal
Robert Siegel, Ricardo Niklas Werner, Stephan Koswig, Matthew Gaskins, Claus Roedel, Felix Aigner
Summary: The study provides detailed information on the development of the guidelines for the treatment of anal cancer. It recommends chemoradiotherapy as the standard treatment for stages II-III, with a suggestion against biopsy in complete clinical response. For stage IV anal cancer, there are only open recommendations, urging further research in this area.
DEUTSCHES ARZTEBLATT INTERNATIONAL
(2021)
Review
Oncology
Jose Alejandro Perez-Fidalgo, Eugenia Ortega, Jordi Ponce, Andres Redondo, Isabel Sevilla, Claudia Valverde, Josep Isern Verdum, Enrique de Alava, Mar Galera Lopez, Gloria Marquina, Ana Sebio
Summary: Uterine sarcomas are rare and diverse, making diagnosis, surgical management, and systemic treatment challenging; treatment decisions should involve a multidisciplinary tumor board; evidence is limited, often based on case series or clinical trials including these tumors with other soft tissue sarcomas. These guidelines summarize the relevant evidence on the diagnosis, staging, pathological disparities, surgical management, systemic treatment, and follow-up of uterine sarcomas.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Tetsuhide Ito, Toshihiko Masui, Izumi Komoto, Ryuichiro Doi, Robert Y. Osamura, Akihiro Sakurai, Masafumi Ikeda, Koji Takano, Hisato Igarashi, Akira Shimatsu, Kazuhiko Nakamura, Yuji Nakamoto, Susumu Hijioka, Koji Morita, Yuichi Ishikawa, Nobuyuki Ohike, Atsuko Kasajima, Ryoji Kushima, Motohiro Kojima, Hironobu Sasano, Satoshi Hirano, Nobumasa Mizuno, Taku Aoki, Takeshi Aoki, Takao Ohtsuka, Tomoyuki Okumura, Yasutoshi Kimura, Atsushi Kudo, Tsuyoshi Konishi, Ippei Matsumoto, Noritoshi Kobayashi, Nao Fujimori, Yoshitaka Honma, Chigusa Morizane, Shinya Uchino, Kiyomi Horiuchi, Masanori Yamasaki, Jun Matsubayashi, Yuichi Sato, Masau Sekiguchi, Shinichi Abe, Takuji Okusaka, Mitsuhiro Kida, Wataru Kimura, Masao Tanaka, Yoshiyuki Majima, Robert T. Jensen, Koichi Hirata, Masayuki Imamura, Shinji Uemoto
Summary: Neuroendocrine neoplasms (NENs) are rare tumors with diverse clinical manifestations. Accurate pathological classification and determination of tumor characteristics are crucial for selecting appropriate treatment strategies. The revised Clinical Practice Guidelines for Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) provide comprehensive directions for the management of NENs, incorporating new evidence and updated concepts.
JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Oncology
Rosario Garcia-Campelo, Ivana Sullivan, Edurne Arriola, Amelia Insa, Oscar Juan Vidal, Patricia Cruz-Castellanos, Teresa Moran, Noemi Reguart, Jon Zugazagoitia, Manuel Domine
Summary: Small-cell lung cancer (SCLC) accounts for about 15% of lung cancers and is highly aggressive. Surgical resection followed by adjuvant therapy is curative for limited-stage SCLC, but only a minority of patients are eligible for surgery. Concurrent chemo-radiotherapy is the standard treatment for inoperable limited-stage SCLC, while combination chemotherapy with programmed death-ligand 1 inhibitors has become the new front-line standard for extensive-stage SCLC. Advances in understanding SCLC biology and new treatment approaches offer potential improvements in patient care.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Review
Cell Biology
Omayma Mazouji, Abdelhak Ouhajjou, Roberto Incitti, Hicham Mansour
Summary: Colorectal cancer is one of the most common cancers globally, with solid biopsy being an essential guide for clinical management, but liquid biopsy has shown significant promise as an alternative tool in various CRC clinical applications, such as early detection, treatment decision-making, and monitoring treatment response.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Ronan J. Kelly, Katherine Bever, Joseph Chao, Kristen K. Ciombor, Cathy Eng, Marwan Fakih, Lipika Goyal, Joleen Hubbard, Renuka Iyer, Holly T. Kemberling, Smitha Krishnamurthi, Geoffrey Ku, Mindy Mintz Mordecai, Van K. Morris II, Andrew Scott Paulson, Valerie Peterson, Manish A. Shah, Dung T. Le
Summary: Gastrointestinal (GI) cancers are a heterogeneous group of malignancies that impose a significant burden globally. Immunotherapy, specifically immune checkpoint inhibitors (ICIs), has transformed the treatment landscape for several GI cancers. However, ICIs have differing biomarker and histology requirements depending on the anatomic site of origin, and they are associated with unique toxicity profiles. To provide guidance to the oncology community, the Society for Immunotherapy of Cancer (SITC) developed a clinical practice guideline on immunotherapy for GI cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Gastroenterology & Hepatology
Jean Frederic Blanc, Audrey Debaillon-Vesque, Gael Roth, Jean Claude Barbare, Anne Sophie Baumann, Valerie Boige, Karim Boudjema, Mohamed Bouattour, Gilles Crehange, Barbara Dauvois, Thomas Decaens, Francois Dewaele, Olivier Farges, Boris Guiu, Antoine Hollebecque, Philippe Merle, Janick Selves, Thomas Aparicio, Isaac Ruiz, Olivier Bouche
Summary: This document summarizes the French Intergroup guidelines on the management of hepatocellular carcinoma (HCC) published in March 2019. Recommendations are graded in 3 categories based on the level of evidence from literature. Diagnosis and staging of HCC rely on clinical, biological, and imaging features, with treatment options varying based on tumor stage and liver function.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
(2021)
